TC BioPharm Files 6-K Report
Ticker: TCBWF · Form: 6-K · Filed: Nov 17, 2025 · CIK: 1872812
Sentiment: neutral
Topics: sec-filing, 6-k, biopharmaceutical
TL;DR
TC BioPharm filed a routine 6-K, no new info.
AI Summary
TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on November 17, 2025. The filing is a report of a foreign private issuer and does not contain specific financial details or operational updates beyond its classification and filing status.
Why It Matters
This filing indicates TC BioPharm is a foreign private issuer and is complying with SEC reporting requirements, but it does not provide new operational or financial information.
Risk Assessment
Risk Level: low — This filing is a standard procedural report and does not contain any new material information that would impact risk.
Key Players & Entities
- TC BioPharm (Holdings) plc (company) — Filer of the report
- 001-41231 (company) — SEC File Number
- 20251117 (date) — Filing date
FAQ
What type of company is TC BioPharm (Holdings) plc?
TC BioPharm (Holdings) plc is classified under Standard Industrial Classification code 2836, which pertains to Biological Products (No Diagnostic Substances).
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, filed for the month of November 2025.
When was this filing submitted to the SEC?
The filing was submitted on November 17, 2025.
What is the principal executive office address for TC BioPharm?
The principal executive offices are located at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, Scotland, United Kingdom.
Does TC BioPharm file its annual reports under Form 20-F or 40-F?
TC BioPharm indicates it files its annual reports under cover of Form 20-F.
Filing Stats: 333 words · 1 min read · ~1 pages · Grade level 20 · Accepted 2025-11-17 08:30:24
Filing Documents
- form6-k.htm (6-K) — 16KB
- 0001493152-25-023773.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TC BIOPHARM (HOLDINGS) PLC Date: November 17, 2025 By: /s/ Martin Thorp Martin Thorp Chief Financial Officer